Monthly Archives: August 2025

The Department of Health and Social Care (DHSC) has today (28/08/2025) confirmed the following list of price concessions for August 2025: Drug Pack size Price concession Acetazolamide 250mg tablets 112 £51.02 Amiodarone 100mg tablets 28 £2.24 Amiodarone 200mg tablets 28 £4.82 Buprenorphine 2mg sublingual tablets sugar free 7 £1.83 Carbocisteine 250mg/5ml oral solution 300 £4.99 Co-amoxiclav [...]

The post August 2025 Price Concessions 4th Update appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has today (27/08/2025) confirmed the following list of price concessions for August 2025: Drug Pack size Price concession Betamethasone 500microgram soluble tablets sugar free 100 £31.95 Bumetanide 1mg tablets 28 £2.94 Buprenorphine 8mg sublingual tablets sugar free 7 £6.00 Co-codamol 30mg/500mg effervescent tablets 32 £2.40 Co-codamol 30mg/500mg effervescent [...]

The post August 2025 Price Concessions 3rd Update appeared first on Community Pharmacy England.

“While implementation of the 2025/26 CPCF continues at pace, our sights are also set on the future,” writes Community Pharmacy England Chief Executive Janet Morrison in a new blog. Despite the funding uplift earlier this year, pharmacy businesses remain in a financially precarious position. Janet explains that the views of pharmacy owners and their experiences [...]

The post Update from our CEO: the next CPCF appeared first on Community Pharmacy England.

Following a decision taken by Eli Lilly to increase its UK list prices for Mounjaro® (Tirzepatide) KwikPen® from 1 September 2025, the Department of Health and Social Care (DHSC) has re-determined the NHS reimbursement prices for all strengths of Mounjaro® dispensed from September to reflect the new, higher list prices. To avoid pharmacy owners dispensing [...]

The post Mounjaro® reimbursement prices redetermined for September 2025 appeared first on Community Pharmacy England.

Dapagliflozin 5mg and 10mg tablets reimbursement prices have decreased following a move from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. More information on the [...]

The post Dapagliflozin tablets – new reimbursement prices from September 2025 appeared first on Community Pharmacy England.